On March 28, 2024, Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, announced it has completed a $50 million Series A financing extension, led by Hevolution. Existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture also participated in the Series A round. Wilson Sonsini Goodrich & Rosati advised Aeovian Pharmaceuticals on patent matters related to the transaction, and manages Aeovian’s patent portfolio strategy.

In addition to the Series A financing, Aeovian also announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer.

The Wilson Sonsini team that advised Aeovian on patent matters related to the transaction includes Julia Minitti, Jose Martinez, and Trevor Lohrey.

For more information, please see Aeovian Pharmaceuticals’ press release.